NA Semax Amidate Nasal (nasal spray)

NA Semax Amidate Nasal is the stabilised Semax variant N-acetyl-Semax-amidate supplied as a ready-mixed nasal spray. The 10mg bottle holds 10mg of peptide in 5 ml of isotonic saline plus 0.4 ml of bacteriostatic water, 5.4 ml in total, which is 1.85mg per millilitre. The metered pump delivers 0.1 ml per actuation, so one spray carries about 185mcg (0.19mg) and a bottle gives about 50 sprays. The 30mg bottle has the same volume but is three times as concentrated: 5.56mg per millilitre and about 556mcg (0.56mg) per spray. There is nothing to dissolve, measure or transfer. The spray is prepared fresh after you order and ships as an express item.

The active substance is Semax, the Russian heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro built on fragment 4-10 of the hormone ACTH, fitted with two protecting groups: an acetyl group at the start of the chain and an amide group at the end. Both are meant to shield the peptide from the enzymes that attack free chain ends and so extend the short residence time of plain Semax. Semax itself is approved in Russia as nasal drops in 0.1 and 1 percent strength; the acetylated and amidated variant is a pure research peptide with no human data of its own. If you prefer to dissolve the powder yourself or to inject, NA Semax Amidate is still available as a vial with its own lexicon entry.

This information is for research and educational purposes only. No medical advice.

Semax descends from ACTH, the hormone that drives cortisol release, but fragment 4-10 has no effect on the adrenal gland. Its best documented action is on neurotrophic factors. Dolotov and colleagues (Brain Research 2006) gave rats a single intranasal dose of 50mcg per kg and measured 1.4 times more BDNF protein, 1.6 times more phosphorylated TrkB receptor and a threefold and twofold rise in BDNF and TrkB messenger RNA in the hippocampus, together with more correct responses in a conditioned avoidance task. BDNF is the messenger that supports neurons during learning, wiring and protection from damage. Effects of Semax on the serotonin and dopamine systems are also described, which fits the sharper focus that users report.

The two protecting groups do not change this mechanism; their job is to let more intact peptide arrive and stay longer. The background: breakdown experiments by the Shevchenko group show that enzymes from nasal mucus, brain membranes and blood attack Semax first at the start of the chain and that mostly the tripeptide Pro-Gly-Pro is left at the end. That is exactly where the acetyl group sits. The same group examined the stability of acetyl-Semax against proteolysis in various biological media in a 2013 short communication (Doklady Biological Sciences). The modification is not free of consequences, though: Magrì and colleagues (Journal of Inorganic Biochemistry 2016) found that acetylation alters how Semax binds copper and that the acetylated peptide no longer protected cultured neuroblastoma cells from copper-induced toxicity, a protection that evidently needs the free chain end. Whether that matters for nootropic use is unknown. Head-to-head comparisons of NA Semax Amidate and Semax in animals or humans do not exist.

The nose is the classic route for Semax; as a medicine in Russia it exists only as nasal drops. Part of the dose travels from the olfactory lining along the olfactory and trigeminal nerves straight into the brain, bypassing the bloodstream and the blood-brain barrier. Shevchenko and colleagues (Russian Journal of Bioorganic Chemistry 2006) measured how fast this happens using tritium-labelled Semax in rats: two minutes after an intranasal dose of 50mcg per kg the peptide was detectable in the brain, but only about 0.1 percent of the dose per gram of tissue, of which 80 percent was still intact and the rest already degraded.

Three practical points follow. First, a nasal dose needs more peptide than an injection because only a fraction gets through, but there is no needle. Second, the effect starts fast while the peptide itself is present only briefly; the downstream changes in growth factors last longer. Third, a 0.1 ml spray is a volume the mucosa absorbs well. Larger volumes at once run down the throat and are swallowed, where peptides are digested rather than active. That argues for several small doses across the day rather than one large one. Whether the acetyl and amide groups improve nasal uptake has not been measured; what is plausible is only that less peptide gets cut up already in the nasal lining.

There are no studies on NA Semax Amidate itself in animals or humans; the evidence is that of Semax plus two chemistry papers on the acetylated form. For Semax the preclinical base is dense: BDNF and TrkB in the hippocampus (Dolotov 2006), the kinetics after nasal dosing (Shevchenko 2006) and dozens of Russian papers on neuroprotection after brain ischaemia, stress and early development. In humans the record is thinner but not empty. Kaplan and colleagues (Neuroscience Research Communications 1996) gave healthy volunteers 0.25 to 1mg of Semax intranasally, about 4 to 16mcg per kg of body weight. They saw EEG changes after brief hyperventilation that resembled those of typical nootropics, plus better work efficiency in operators lasting 20 to 24 hours; the paper is old, small and has never been repeated at scale. Lebedeva and colleagues (Bulletin of Experimental Biology and Medicine 2018) used resting-state functional MRI in 24 healthy volunteers and showed that a nasal dose of 1 percent Semax, compared with placebo, altered the default mode network as early as 5 and 20 minutes later, with a larger anterior component in the medial frontal cortex. That proves nasal Semax reaches the brain quickly and measurably, but says nothing about better performance in daily life.

The Russian approval of Semax rests mainly on stroke studies with the 1 percent drops and daily amounts in the milligram range, far above anything used for focus and memory in a research context. On the acetylated form there is the stability paper by Shevchenko and colleagues (2013) and the copper and zinc study by Magrì and colleagues (2016), both in the test tube or in cell culture. What is missing are comparisons of NA Semax Amidate against Semax in a living organism, half-life data and any human study. Honestly summarised: the mechanism of the parent molecule is well described, the idea behind the protecting groups is chemically plausible. Proof that they make a difference in humans is still outstanding.

There are no safety data specific to the acetylated and amidated form, so the Semax profile serves as the guide. The Russian prescribing information for the Semax drops lists a single side effect: mild irritation of the nasal mucosa with prolonged use. It describes the peptide as practically non-toxic. Beyond that, users report head pressure, inner restlessness and poorer sleep after late doses, which fits the activating profile, plus a dry or burning nasal lining and sneezing. Serious adverse effects are rarely described in the literature, but data on months of continuous use are lacking, for Semax too. The spray is made up in 5 ml of saline with only 0.4 ml of bacteriostatic water, so the benzyl alcohol from it is heavily diluted and barely preserves anything; hygiene at the nozzle therefore matters more than with a vial of plain bacteriostatic water.

The Russian label excludes several groups. That is a sensible guide: acute psychoses, disorders dominated by anxiety, a history of seizures, pregnancy and breastfeeding, hypersensitivity to any component, plus children under 5 for the 0.1 percent drops. From a practical angle add: an acute cold or sinus infection, because uptake becomes unpredictable and irritation stronger, injured or recently operated nasal mucosa and anyone under 18. If you take medication acting on dopamine or serotonin, such as antidepressants or stimulants, do not try the combination without talking to a doctor, because Semax influences both systems in animal studies. If irritation or sleep problems persist, stop rather than push through.

The spray arrives freshly prepared and belongs in the fridge straight away. Before the first use, pump once or twice into the air until an even mist appears; only then is the amount per spray reliable. Hold the bottle upright while spraying, do not push the nozzle in deep and aim it slightly outward toward the side of the nostril, not at the septum, where the lining is more sensitive. If a spray clearly misses, do not top it up; the next dose simply proceeds as normal.

After each use wipe the nozzle with a clean tissue and put the cap back on so nothing dries in and no germs reach the opening. The bottle is personal: do not share it, not even within the household. If it has not been used for a few days, pump once into the air before using it in the nose again. If the solution turns gel-like, lumpy or smells different, stop using it. Slight cloudiness on its own is not a reason. Do not mix up the two strengths: the 30mg bottle delivers three times the amount per spray, so check the label before every dose if both are in the fridge.

Keep the bottle in the fridge at 2 to 8 degrees, upright, capped and protected from light, for example in its outer box. Do not freeze it: freezing can damage peptides and the pump. Chemically, Semax-type peptides are stable in cold solution for months, the Russian Semax drops have a two-year shelf life unopened. The protecting groups of NA Semax Amidate should if anything improve that. The limiting factor for the spray is hygiene, because the solution carries only the small share of preservative that comes with the 0.4 ml of bacteriostatic water. Count on two to three months after opening and use the bottle up within that time; at 0.37mg a day the 10mg bottle is empty after a good three weeks anyway.

For a few hours of transport a small cooler bag or a jacket pocket is fine; avoid a full day of warmth. If the spray has sat at room temperature for some hours it is not spoiled, just chill it again promptly. If you pause, leave the spray in the fridge and pump once into the air before the next use.